# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>HEADER</td>
<td>1</td>
</tr>
<tr>
<td>ABSTRACT</td>
<td>1</td>
</tr>
<tr>
<td>Plain Language Summary</td>
<td>2</td>
</tr>
<tr>
<td>BACKGROUND</td>
<td>3</td>
</tr>
<tr>
<td>OBJECTIVES</td>
<td>4</td>
</tr>
<tr>
<td>METHODS</td>
<td>4</td>
</tr>
<tr>
<td>RESULTS</td>
<td>7</td>
</tr>
<tr>
<td>Figure 1</td>
<td>8</td>
</tr>
<tr>
<td>DISCUSSION</td>
<td>9</td>
</tr>
<tr>
<td>AUTHORS’ CONCLUSIONS</td>
<td>10</td>
</tr>
<tr>
<td>ACKNOWLEDGEMENTS</td>
<td>10</td>
</tr>
<tr>
<td>REFERENCES</td>
<td>10</td>
</tr>
<tr>
<td>CHARACTERISTICS OF STUDIES</td>
<td>14</td>
</tr>
<tr>
<td>DATA AND ANALYSES</td>
<td>17</td>
</tr>
<tr>
<td>CONTRIBUTIONS OF AUTHORS</td>
<td>17</td>
</tr>
<tr>
<td>DECLARATIONS OF INTEREST</td>
<td>17</td>
</tr>
<tr>
<td>SOURCES OF SUPPORT</td>
<td>17</td>
</tr>
<tr>
<td>DIFFERENCES BETWEEN PROTOCOL AND REVIEW</td>
<td>17</td>
</tr>
</tbody>
</table>
Oral versus inhaled antibiotics for bronchiectasis

Sally Spencer¹, Lambert M Felix², Stephen J Milan³, Rebecca Normansell⁴, Pieter C Goeminne⁵,⁶, James D Chalmers⁷, Tim Donovan⁸

¹Postgraduate Medical Institute, Edge Hill University, Ormskirk, UK. ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK. ³Medical School, Lancaster University, Lancaster, UK. ⁴Cochrane Airways, Population Health Research Institute, St George’s, University of London, London, UK. ⁵AZ Nikolaas, Sint-Niklaas, Belgium. ⁶UZ Leuven, Leuven, Belgium. ⁷University of Dundee, Ninewells Hospital and Medical School, Dundee, UK. ⁸Medical and Sport Sciences, University of Cumbria, Lancaster, UK

Contact address: Sally Spencer, Postgraduate Medical Institute, Edge Hill University, St Helens Road, Ormskirk, Lancashire, L39 4QP, UK. spencesa@edgehill.ac.uk

Editorial group: Cochrane Airways Group.


Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Bronchiectasis is a chronic inflammatory disease characterised by a recurrent cycle of respiratory bacterial infections associated with cough, sputum production and impaired quality of life. Antibiotics are the main therapeutic option for managing bronchiectasis exacerbations. Evidence suggests that inhaled antibiotics may be associated with more effective eradication of infective organisms and a lower risk of developing antibiotic resistance when compared with orally administered antibiotics. However, it is currently unclear whether antibiotics are more effective when administered orally or by inhalation.

Objectives

To determine the comparative efficacy and safety of oral versus inhaled antibiotics in the treatment of adults and children with bronchiectasis.

Search methods

We identified studies through searches of the Cochrane Airways Group's Specialised Register (CAGR), which is maintained by the Information Specialist for the group. The Register contains trial reports identified through systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, CINAHL, AMED, and PsycINFO, and handsearching of respiratory journals and meeting abstracts. We also searched ClinicalTrials.gov and the WHO trials portal. We searched all databases in March 2018 and imposed no restrictions on language of publication.

Selection criteria

We planned to include studies which compared oral antibiotics with inhaled antibiotics. We would have considered short-term use (less than four weeks) for treating acute exacerbations separately from longer-term use as a prophylactic (4 weeks or more). We would have considered both intraclass and interclass comparisons. We planned to exclude studies if the participants received continuous or high-dose antibiotics immediately before the start of the trial, or if they have received a diagnosis of cystic fibrosis (CF), sarcoidosis, active allergic bronchopulmonary aspergillosis or active non-tuberculous Mycobacterial infection.
Data collection and analysis

Two review authors independently applied study inclusion criteria to the searches and we planned for two authors to independently extract data, assess risk of bias and assess overall quality of the evidence using GRADE criteria. We also planned to obtain missing data from the authors where possible and to report results with 95% confidence intervals (CIs).

Main results

We identified 313 unique records through database searches and a further 21 records from trial registers. We excluded 307 on the basis of title and abstract alone and a further 27 after examining full-text reports. No studies were identified for inclusion in the review.

Authors’ conclusions

There is currently no evidence indicating whether orally administered antibiotics are more beneficial compared to inhaled antibiotics. The recent ERS bronchiectasis guidelines provide a practical approach to the use of long-term antibiotics. New research is needed comparing inhaled versus oral antibiotic therapies for bronchiectasis patients with a history of frequent exacerbations, to establish which approach is the most effective in terms of exacerbation prevention, quality of life, treatment burden, and antibiotic resistance.

Plain Language Summary

Oral versus inhaled antibiotics for people with bronchiectasis

Review question

We wished to know whether oral antibiotics (taken by mouth) or inhaled antibiotics are more effective for reducing the duration and frequency of infective episodes of bronchiectasis, admissions to hospital and side effects, as well as reducing the risk of chest infections not responding to treatment with antibiotics.

Background

Bronchiectasis is a long-term incurable condition where people get repeated bacterial chest infections that lead to frequent cough, breathlessness and mucus production. These often occur three or more times a year and require treatment with antibiotics, either short-term for the presenting chest infection, or long-term to prevent chest infections recurring. It was once thought to be an uncommon disease but recent figures show that up to 5 people in every 1000 may have bronchiectasis and the death rate for people with the condition may be more than twice that of the general population.

Antibiotics are commonly used to treat chest infections in people with bronchiectasis, to eliminate the specific types of bacteria that cause the infection. Some antibiotics are more effective against particular types of bacteria compared to others, and these different types of bacteria can develop resistance to treatment with antibiotics, making them less effective and reducing the subsequent choice of antibiotic. Antibiotics can also be given to people in different ways, such as by mouth in pill form or breathed in as an inhalation.

We do not currently know which method of administering antibiotics, orally or by inhalation, is the most effective for treating recurrent chest infections in terms of eliminating the bacteria, reducing the chances of people developing resistance to antibiotics and reducing the symptoms of bronchiectasis.

We searched for all the published and unpublished available evidence, up until March 2018, which compared orally administered antibiotics versus inhaled antibiotics.

Study characteristics

While there have been a few studies investigating the benefits of antibiotics for people with bronchiectasis, none have compared orally administered antibiotics with inhaled antibiotics.

Quality of the evidence

There is no high-quality evidence available to determine whether oral or inhaled antibiotics are more helpful for people with bronchiectasis. More research studies are needed to evaluate the effectiveness of oral antibiotics compared to inhaled antibiotics for reducing the rate of chest infections and the chances of developing resistance to antibiotic therapy.
BACKGROUND

Description of the condition

Bronchiectasis is a chronic inflammatory lung disease that presents with cough, sputum production and recurrent respiratory tract infections (Pasteur 2010). It is defined radiologically by the presence of permanently dilated airways usually visualised on computed tomography (CT). Bronchiectasis represents a final common pathway of multiple disorders with the most common associations being with severe infections (pneumonia, childhood infection and Mycobacterial infection), allergic bronchopulmonary aspergillosis, rheumatological diseases, inflammatory bowel disease and disorders of mucociliary clearance such as primary ciliary dyskinesia (Lonni 2015). Treatments for bronchiectasis have historically been extrapolated from cystic fibrosis with a focus on antibiotic treatments and physiotherapy (Chalmers 2016).

Although previously considered a relatively rare disease (Kolbe 1996), bronchiectasis appears to be increasing, with higher rates in developing countries, women and those aged over 60 years (Chang 2003; Weycker 2005; Habesoglu 2011; Seitz 2012). Prevalence rates may also be higher in children from ethnic populations, for example indigenous Australians (up to 14 per 1000) and Native Alaskan children (up to 20.5 per 1000) (Singleton 2000; Chang 2002). International prevalence rates in the general population are variable, ranging from 0.5 per 100,000 in Finland to 3.7 per 100,000 in New Zealand (European Lung White Book 2013).

More recent data from the UK reported an increase of over 60% in prevalence over a nine-year period, with 263,000 adults living with bronchiectasis in 2013 (Quint 2016). Incidence rates increased by 63% to 35 per 100,000 in women and 27 per 100,000 in men, with over 15,000 new cases in 2013. However, increased prevalence may be partly attributable to increased awareness of bronchiectasis and more efficient detection through CT scanning (Goeminne 2016).

Mortality rates increased by 3% per year during a six-year period to 2007 in England and Wales (Roberts 2010). In the USA, hospitalisations also rose annually by 3% over a nine-year period (Seitz 2010). Average European mortality rates from 2005 to 2009 are estimated at 0.3 per 100,000 general population in EU countries (from 0.01 in Germany to 1.18 in the UK) and 0.2 per 100,000 in nine non-EU countries (from 0.01 in Azerbaijan to 0.67 in Kyrgyzstan) (European Lung White Book 2013). Recent age-adjusted mortality rates for the UK were more than twice that of the general population (2.26 times higher in women; 2.14 times higher in men) (Quint 2016).

Description of the intervention

Bronchiectasis is characterised by a common pathophysiological pathway that consists of a vicious cycle. Three elements play a pivotal role in this cycle: inflammation, infection and airway damage by enzymatic components. In this cycle, infection or colonisation by various micro-organisms cause an inflammatory response. When this inflammation is not able to clear the micro-organism, the inflammation can become chronic and even excessive compared to the bacterial burden. This can then finally result in airway damage and remodelling (Goeminne 2010).

Interventions aiming to reduce or break this vicious cycle often focus on the treatment of the chronic bacterial infection. Data show that these chronic infections are most often caused by Gram-negatives, with a special focus on Pseudomonas aeruginosa as this has been linked with more severe disease and increased morbidity and mortality (Wilson 2016). To treat or eradicate these chronic infections, long courses and high dosage of systemic antibiotic treatment are often required. This is frequently accompanied by side effects and can also result in resistance. Therefore, inhaled antibiotics are increasingly being considered, as they can deliver high concentrations of the antibiotic at the site of infection with less systemic absorption and toxicity, but can result in increased airway irritation or bronchospasm (Geller 2009).

How the intervention might work

A recent Cochrane review of 18 trials in patients with bronchiectasis receiving prolonged antibiotics, showed that there was a significant reduction of exacerbation risk (Hnin 2015). Furthermore, recent data clearly suggest an important relationship between inflammation and bacterial load/presence in bronchiectasis. Chronic Pseudomonas aeruginosa infection was associated with increased matrix metalloprotease activity and a higher bacterial load was associated with an increase in hospitalisations, exacerbations and symptom severity (Chalmers JD 2012; Goeminne 2014). Chalmers et al also showed that both short- and long-term antibiotic treatment significantly reduced airway and systemic inflammation. This is in line with a series of long-term systemic antibiotic therapy trials with macrolides, proving that long-term oral macrolides are useful for patients with bronchiectasis in reducing exacerbations and improving clinical symptoms (Wong 2012; Altenburg 2013; Serisier 2013).

It is speculated that macrolides not only act through their antibacterial activity but also have anti-inflammatory and immunomodulatory effect (Altenburg 2011a). These long-term oral macrolide treatments, however, raise some concerns as to safety and bacterial resistance (Altenburg 2011b). Inhaled antibiotics may provide an effective suppressive antibiotic therapy with an acceptable safety profile in adult patients with stable bronchiectasis and chronic bronchial infection. Their use has been widespread in CF since the early 1990s, as inhaled antibiotics improve lung function and reduce exacerbation rates (Ryan 2011). For inhaled antibiotics, different antibiotic regimens have been investigated in non-CF bronchiectasis, including inhaled amikacin, aztreonam, ciprofloxacin, gentamicin, colistin and tobramycin. The antibiotics chosen often have a concentration-dependent ef-
fect, where a greater area under the curve/minimum inhibitory concentration ratio improves bacterial killing (Restrepo 2015). As resistance is one of the concerns in chronic antibiotic treatment, these inhaled antibiotics may achieve very high concentrations of the drug in the airways, overcoming bacterial resistance (Dudley 2008; Rubin 2008; Quon 2014). On the other hand, inhalation antibiotic treatment is hampered by a delivery that is not uniform, creating a concentration gradient with lower concentrations in deeper parts of the lung (Rubin 2008). In non-CF bronchiectasis, a recent review found that long-term inhaled antibiotics can effectively reduce the sputum bacterial density, increase Pseudomonas aeruginosa eradication and attenuate the risk of exacerbation, but with higher risk of wheeze and bronchospasm (Yang 2016).

Why it is important to do this review
In meta-analyses of trials involving participants with non-CF bronchiectasis, authors have concluded that inhaled antibiotics reduced sputum bacterial load and the risk of acute exacerbation, with an acceptable safety profile, when compared to symptomatic treatment or placebo (Brodt 2014; Yang 2016). However, in reality, clinicians will often be faced with the choice between various routes of delivering antibiotics, not only the choice of whether or not to give them. A comparison between the oral and inhaled route was highlighted as a priority in a recently published overview of interventions for bronchiectasis (Welsh 2015). The potential benefits of improved bacterial killing and reduced risk of bacterial resistance described above need to be weighed against the cost of drug delivery via inhalation and specific side effects associated with this route, such as bronchospasm and wheeze (BNF (online); Brodt 2014; Yang 2016).
Therefore in this review we will include studies that directly compare the effectiveness and safety of delivering antibiotics by inhalation or orally, both in an acute setting and for longer-term prophylaxis in people with bronchiectasis. We intend to summarise the evidence to provide the most up-to-date information for guideline developers, clinicians and patients, and highlight future research needs. This review is being conducted alongside four other closely related Cochrane reviews on macrolide antibiotics for bronchiectasis (Kelly 2016); dual antibiotics for bronchiectasis (Felix 2017); head-to-head trials of antibiotics for bronchiectasis (Kaehne 2017); and continuous versus intermittent antibiotics for bronchiectasis (Donovan 2017).

OBJECTIVES
To determine the comparative efficacy and safety of oral versus inhaled antibiotics in the treatment of adults and children with bronchiectasis.

METHODS

Criteria for considering studies for this review

Types of studies
We planned to include randomised controlled trials (RCTs), reported as full-text or published as abstract only or unpublished data.

Types of participants
We planned to include adults and children diagnosed with bronchiectasis by bronchography, plain film chest radiograph, or high-resolution computed tomography. We planned to exclude studies if the participants received continuous or high-dose antibiotics immediately before the start of the trial, or if they had received a diagnosis of cystic fibrosis (CF), sarcoidosis, active allergic bronchopulmonary aspergillosis or active non-tuberculous Mycobacterial infection.

Types of interventions
We planned to include studies comparing oral antibiotics with inhaled antibiotics. We would have considered short-term use (less than 4 weeks) for treating acute exacerbations separately from longer-term use as a prophylactic (4 weeks or more). We would have considered both intraclass and interclass comparisons. We planned to include the following comparison groups.
1. Inhaled aminoglycosides versus oral antibiotics
2. Inhaled polymyxin versus oral antibiotics
3. Inhaled beta-lactam versus oral antibiotics

Types of outcome measures

Primary outcomes
We planned to include the following primary outcomes for short-term therapy, longer-term therapy or both, as indicated.
1. Duration of exacerbation (short-term)
2. Exacerbation (both), e.g. frequency during follow-up or time to first exacerbation
3. Hospitalisations due to exacerbations (both)
4. Serious adverse events (both)

Secondary outcomes
1. Response rates as defined by study authors, e.g. diary cards of physician global assessment
2. Sputum volume and purulence
3. Measures of lung function, e.g. forced expiratory volume in one second (FEV₁)
4. Adverse events, e.g. cardiac arrhythmias, gastrointestinal symptoms, hearing impairment, bronchospasm
5. Mortality
6. Emergence of resistance to antibiotics or treatment emergent pathogens
7. Exercise capacity, e.g. Six-Minute Walk Test (6MWT)
8. Quality of life (QOL), e.g. St George Respiratory Questionnaire (SGRQ) or alternative QOL tools
9. Eradication of pathogens

Reporting one or more of the outcomes listed here in the study was not used as an inclusion criterion for the review. We planned to include the above secondary outcomes for both short-term and long-term therapy.

**Search methods for identification of studies**

**Electronic searches**

We identified studies from the Cochrane Airways Specialised Register, which is maintained by the Information Specialist for the group. The Cochrane Airways Specialised Register contains studies identified from several sources:
1. Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL), through the Cochrane Register of Studies Online (crs.cochrane.org);
2. Weekly searches of MEDLINE Ovid SP, 1946 to date;
3. Weekly searches of Embase Ovid SP, 1974 to date;
4. Monthly searches of PsycINFO Ovid SP, 1967 to date;
5. Monthly searches of CINAHL EBSCO (Cumulative Index to Nursing and Allied Health Literature), 1937 to date;
6. Monthly searches of AMED EBSCO (Allied and Complementary Medicine);
7. Handsearches of the proceedings of major respiratory conferences.

Studies contained in the Specialised Register are identified through search strategies based on the scope of Cochrane Airways. Details of these strategies, as well as a list of handsearched conference proceedings are in Appendix 1. See Appendix 2 for search terms used to identify studies for this review.

We also conducted a search of US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (www.clinicaltrials.gov) and the World Health Organization International Clinical Trials Registry Platform (apps.who.int/trialssearch). We searched all databases from their inception to 5 March 2018, and we imposed no restriction on language of publication.

**Searching other resources**

We planned to check the reference lists of all primary studies and review articles for additional references. As there are multiple manufacturers of both oral and inhaled antibiotics and many are off-patent, we did not conduct a search of manufacturers’ websites for study information.

We planned to search for errata or retractions from included studies published in full text on PubMed and report the date of this search within the review.

**Data collection and analysis**

**Selection of studies**

Two review authors (TD and RN) screened the titles and abstracts of the search results independently and coded them as ‘retrieve’ (eligible or potentially eligible/unclear) or ‘do not retrieve’. We then retrieved the full-text study reports of all potentially eligible studies and two review authors (TD and RN) independently screened them for inclusion, recording the reasons for exclusion of ineligible studies. We did not have any disagreements, but if we had then we planned to resolve this through discussion or, if required, by consulting a third person/review author (SS/SJM). We planned to identify and exclude duplicates and collate multiple reports of the same study so that each study, rather than each report, would be the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram and ‘Characteristics of excluded studies’ table (Moher 2009).

**Data extraction and management**

We planned to use a data collection form for study characteristics and outcome data, which was used for a similar review on a closely related topic. For future updates, we will extract the following study characteristics from included studies.

1. Methods: study design, total duration of study, details of any ‘run-in’ period, number of study centres and location, study setting, withdrawals and date of study.
2. Participants: N, mean age, age range, gender, severity of condition, diagnostic criteria, baseline lung function, smoking history, inclusion criteria and exclusion criteria.
3. Interventions: intervention, comparison, concomitant medications and excluded medications.
4. Outcomes: baseline exacerbation data (e.g. frequency, duration), primary and secondary outcomes specified and collected, and time points reported.
5. Notes: funding for studies and notable conflicts of interest of trial authors.

If we identify eligible trials in future updates of this review, two review authors (RN and TD) will independently extract outcome data from included studies. We will note in the ‘Characteristics of included studies’ table if outcome data were not reported in a usable way. We will resolve disagreements by consensus or by involving a third person/review author (SS/SJM). One review author will transfer data into the Review Manager file (RevMan 2014).
This entered data will be double-checked for accuracy by another review author by comparing the data presented in the systematic review with the study reports.

**Assessment of risk of bias in included studies**

In future updates, if any studies meet the inclusion criteria, then two review authors will assess risk of bias independently for each study using the criteria outlined in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011). We will resolve any disagreements by discussion or by involving another author (SS/SJM). We will assess the risk of bias according to the following domains:

1. random sequence generation;
2. allocation concealment;
3. blinding of participants and personnel;
4. blinding of outcome assessment;
5. incomplete outcome data;
6. selective outcome reporting; and
7. other bias.

If we identify eligible trials in future updates of this review, we will judge each potential source of bias as high, low or unclear risk, and provide a quote from the study report together with a justification for our judgement in the ‘Risk of bias’ table. We will summarise the ‘Risk of bias’ judgements across different studies for each of the domains listed. We plan to consider blinding separately for different key outcomes where necessary (e.g. for unblinded outcome assessment, risk of bias for all-cause mortality may be very different than for a patient-reported quality of life scale). Where information on risk of bias relates to unpublished data or correspondence with a trialist, we will note this in the ‘Risk of bias’ table.

When considering treatment effects, we will take into account the risk of bias for the studies that contributed to that outcome.

**Assessment of bias in conducting the systematic review**

We conducted the review according to this published protocol and planned to justify any deviations from it in the ‘Differences between protocol and review’ section of the systematic review.

**Measures of treatment effect**

If we identify eligible trials in future updates of this review, we will adhere to the following data analysis plan. We will analyse dichotomous data as odds ratios (ORs) and continuous data as mean differences (MDs) or standardised mean differences (SMDs). We will enter data presented as a scale (e.g. quality of life measures) with a consistent direction of effect. We will describe skewed data narratively (for example, as medians and interquartile ranges for each group).

We will undertake meta-analyses only where this is meaningful; that is, if the treatments, participants and the underlying clinical question are similar enough for pooling to make sense. Where multiple trial arms are reported in a single study, we will include only the relevant arms. If two comparisons (e.g. drug A versus placebo and drug B versus placebo) are combined in the same meta-analysis, we will either combine the active arms or halve the control group to avoid double-counting.

If adjusted analyses are available (ANOVA or ANCOVA) we will use these as a preference in our meta-analyses. If both change from baseline and endpoint scores are available for continuous data, we will use change from baseline scores unless there is low correlation between measurements in individuals. If a study reports outcomes at multiple time points (repeated observations), we will perform separate analyse for different periods of follow-up.

We will use intention-to-treat (ITT) analyses where they are reported (i.e. all those who were randomised are analysed) instead of completer or per protocol analyses.

**Unit of analysis issues**

If we identify eligible trials in future updates of this review, we will adhere to the following plan. For dichotomous outcomes, we will use participants, rather than events, as the unit of analysis (i.e. number of children admitted to hospital, rather than number of admissions per child). However, if rate ratios are reported in a study, we will analyse them on this basis. We will only meta-analyse data from cluster-RCTs if the available data have been adjusted (or can be adjusted), to account for the clustering.

**Dealing with missing data**

If we identify eligible trials in future updates of this review, we will contact investigators or study sponsors in order to verify key study characteristics and obtain missing numerical outcome data where possible (e.g. when a study is identified as an abstract only). Where this is not possible, and the missing data are thought to introduce serious bias, we will take this into consideration in the GRADE rating for affected outcomes.

**Assessment of heterogeneity**

If we identify eligible trials in future updates of this review, we will use the $I^2$ statistic to measure heterogeneity among the studies in each analysis. If we identify substantial heterogeneity we will report it and explore the possible causes by prespecified subgroup analysis.

**Assessment of reporting biases**

If we identify eligible trials in future updates of this review, and are able to pool more than 10 studies, we will create and examine a funnel plot to explore possible small study and publication biases.
Data synthesis
If we identify eligible trials in future updates of this review, we will use a random-effects model and perform a sensitivity analysis with a fixed-effect model.

'Summary of findings' table
If we identify eligible trials in future updates of this review, we will create a 'Summary of findings' table using the following outcomes: duration of exacerbations, exacerbations (frequency and time to first exacerbation), frequency of hospitalisations due to exacerbations, serious adverse events, mortality and quality of life. We will use the five GRADE considerations (risk of bias, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of a body of evidence as it relates to the studies that contribute data for the prespecified outcomes. We will use the methods and recommendations described in Section 8.5 and Chapter 12 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011), using GRADEpro software (GRADEpro GDT). We will justify all decisions to downgrade the quality of studies using footnotes and we will make comments to aid the reader's understanding of the review where necessary.

Subgroup analysis and investigation of heterogeneity
If we identify eligible trials in future updates of this review, we plan to carry out the following subgroup analyses.
1. Adults versus children (18 years or younger)
2. Patients chronically infected with Pseudomonas aeruginosa versus those not infected with Pseudomonas aeruginosa
3. Macrolide versus non-macrolide oral antibiotic
We will use the following outcomes in subgroup analyses.
1. Exacerbation duration (short-term therapy)
2. Exacerbation, e.g. frequency during follow-up or time to first exacerbation
3. Hospitalisation due to exacerbations
4. Adverse events
We will use the formal test for subgroup interactions in Review Manager (RevMan 2014).

Sensitivity analysis
If we identify eligible trials in future updates of this review, we plan to carry out the following sensitivity analyses, removing the studies judged as high risk of bias from the primary outcome analyses.
1. Exacerbation duration (short-term therapy)
2. Exacerbation, e.g. frequency during follow-up or time to first exacerbation (both)
3. Hospitalisation due to exacerbations
4. Adverse events
We will compare the results from a fixed-effect model with the random-effects model.

RESULTS

Description of studies

Results of the search
We identified 313 unique records through database searches and a further 21 records from trial registries (www.ClinicalTrials.gov and www.who.int/ictrp/en/). We excluded 307 records on the basis of title and abstract and a further 27 after examining the full text. Details of the search are shown in the flow diagram Figure 1. The searches were conducted in March 2018.
Figure 1. Study flow diagram

313 records identified through database searching
21 additional records identified through other sources

334 records after duplicates removed

334 records screened
307 records excluded

27 full-text articles assessed for eligibility
27 full-text articles excluded, with reasons

0 studies included in qualitative synthesis

0 studies included in quantitative synthesis (meta-analysis)
Included studies
We did not identify any randomised controlled trials (RCTs) meeting our prespecified inclusion criteria.

Excluded studies
We excluded 27 studies after reviewing the full-text publication. Reasons for exclusion were: trial compared an inhaled or nebulised antibiotic to placebo or usual care (n = 20); the record was a letter to editor (n = 2); trial compared addition of inhaled antibiotics to oral antibiotics (n = 2); trial compared intravenous followed by oral antibiotics for an acute exacerbation of bronchiectasis to a full intravenous course of antibiotics (n = 1); trial was not randomised and investigated impact of long- and short-term antibiotic treatment on inflammation (n = 1); and trial compared addition of inhaled antibiotics to intravenous antibiotics versus intravenous antibiotics alone (n = 1). See Characteristics of excluded studies.

Risk of bias in included studies
We did not identify any RCTs meeting our prespecified inclusion criteria.

Effects of interventions
We did not identify any RCTs meeting our prespecified inclusion criteria.

DISCUSSION

Summary of main results
It was not possible to achieve our aim to provide an overview of the effectiveness of oral versus inhaled antibiotics for bronchiectasis with respect to our predefined outcomes; our comprehensive search found no randomised controlled trials meeting our predefined inclusion criteria (see: Criteria for considering studies for this review). The absence of evidence addressing this question is a cause for considerable concern as uncertainties remain regarding the most effective route of administration for reducing exacerbations and minimising the development of antibiotic resistance.

Overall completeness and applicability of evidence
Unfortunately we were unable to assess the completeness and applicability of evidence on oral versus inhaled antibiotics for bronchiectasis as no studies met our inclusion criteria.

Quality of the evidence
We were unable to consider the quality of evidence comparing oral versus inhaled antibiotics for bronchiectasis as no relevant clinical trials were available.

Potential biases in the review process
Our searches for relevant clinical trials were extensive and comprehensive, with expert support from the Cochrane Airways Group.

Agreements and disagreements with other studies or reviews
We did not identify any systematic reviews or clinical trials relevant to the comparison between oral versus inhaled antibiotics for bronchiectasis.

European Respiratory Society guidelines for the management of bronchiectasis suggest use of an inhaled antibiotic over oral antibiotics for adults with bronchiectasis and chronic P. aeruginosa infection, unless inhaled antibiotics are contraindicated, not tolerated or ineffective (Polverino 2017). Macrolides (azithromycin, erythromycin) are recommended in preference to inhaled antibiotics for adults with bronchiectasis and no infection with P. aeruginosa. When macrolides are contraindicated, not tolerated or ineffective, other oral antibiotics are recommended (Polverino 2017). A Cochrane review on cystic fibrosis reported a reduction in pulmonary exacerbations and a small improvement in lung function over six months with macrolide antibiotics (Southern 2012). However, there are no randomised controlled trials of oral versus inhaled antibiotic treatments to prevent exacerbations in cystic fibrosis, and clinical guideline recommendations are inconsistent.

The USA Cystic Fibrosis Foundation guidelines recommend both oral azithromycin and inhaled tobramycin in patients with cystic fibrosis bronchiectasis chronically infected with P. aeruginosa (Flume 2007). In contrast, UK guidelines on cystic fibrosis recommend nebulised antipseudomonal antibiotics for patients with chronic P. aeruginosa infection, and azithromycin as an additional therapy for deteriorating patients (Cystic Fibrosis Trust 2009). In both cystic fibrosis and bronchiectasis guidelines, most of the ev-
idence for treating patients with \textit{P. aeruginosa} infection is from studies of inhaled antimicrobials and so these are often used first.

\section*{Authors’ Conclusions}

\subsection*{Implications for practice}

There is currently no evidence from randomised controlled trials to indicate whether orally administered antibiotics are more or less beneficial than inhaled antibiotics. Until such evidence is available, practitioners may consider consulting local, national and international guidelines, such as the European Respiratory Society guidelines for the management of bronchiectasis (Polverino 2017).

\subsection*{Implications for research}

The above recommendations from the European Respiratory Society guidelines are not based on direct evidence as there are no studies that compare inhaled versus oral antibiotics, either in patients with \textit{P. aeruginosa} infection or in other populations of patients (Polverino 2017). The recommendations are based largely on the experience of inhaled antibiotics in cystic fibrosis, and are influenced by the fact that most trials to date have used inhaled antibiotics for patients with \textit{P. aeruginosa} infection and oral antibiotics in populations without \textit{P. aeruginosa} (Chalmers 2015). The primary objective of both oral and inhaled antibiotic therapy in bronchiectasis is the prevention of exacerbations (Hill 2017).

It would therefore be desirable to see randomised controlled trials comparing the administration of inhaled versus oral antibiotic therapies for bronchiectasis patients with a history of frequent exacerbations, with the aim of establishing which approach is most effective in terms of exacerbation prevention, quality of life, treatment burden, and antibiotic resistance (Aliberti 2016b). Since bronchiectasis is a clinically heterogeneous disease with four potential disease clusters (\textit{Pseudomonas} infection, other chronic infection, daily sputum, dry bronchiectasis), it is likely that different patient populations will respond differently to inhaled or oral antibiotic treatments, and so it is a research priority to identify clinical phenotypes of subgroups likely to respond to each therapy (Aliberti 2016a).

\section*{Acknowledgements}

We thank Edge Hill University and Lancaster University for their support in the development of this review. Dr Chalmers and Dr Goeminne acknowledge support from the European Bronchiectasis Network (EMBARC), which is funded by the European Respiratory Society.

We would also like to thank the Cochrane Airways Group for their support.

The \textbf{Background} and \textbf{Methods} sections of this protocol are based on a standard template used by Cochrane Airways.

This project was supported by the National Institute for Health Research (NIHR), via Cochrane Infrastructure funding to the Cochrane Airways Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, National Health Service, or the Department of Health.

\section*{References}

\begin{itemize}
  \item \textbf{Antoniou 2011 (published data only)}
    \begin{itemize}
    \end{itemize}
  \item \textbf{Bilton 2006 (published data only)}
    \begin{itemize}
    \end{itemize}
  \item \textbf{Chalmers 2012 (published data only)}
    \begin{itemize}
    \end{itemize}
  \item \textbf{Fiel 2000 (published data only)}
    \begin{itemize}
      \item Fiel SB. The relationship between antimicrobial efficacy
    \end{itemize}
\end{itemize}

Flume 2013 *(published data only)*


Hampel 2011 *(published data only)*


Labiris 1999 *(published data only)*


Ledson 2000 *(published data only)*


Murray 2000 *(published data only)*


NCT00749866 2008 *(published data only)*

NCT00749866. Long term nebulised gentamicin in patients with bronchiectasis. [Can long term nebulised gentamicin reduce the bacterial burden, break the vicious cycle of inflammation and improve quality of life in patients with bronchiectasis?]. clinicaltrials.gov/ct2/show/NCT00749866 (first received 9 September 2008).

NCT01313624 2011 *(published data only)*

NCT01313624. A study to see if AZLI (an inhaled antibiotic) is effective in treating adults with non-cf bronchiectasis - AIR-BX1 [A phase 3, double-blind, multicenter, randomized, placebo-controlled trial evaluating repeated courses of aztreonam for inhalation solution in subjects with non-cf bronchiectasis and gram-negative endobronchial infection]. clinicaltrials.gov/ct2/show/NCT01313624 (first received 14 March 2011).

NCT01677403 2012 *(published data only)*

NCT01677403. A study to access safety and efficacy of nebulized tobramycin in patients with bronchiectasis. [A randomized, controlled study to evaluate the efficacy, indications, adverse reactions and resistance of combined administration of nebulized tobramycin compared with systemic administration alone in patients with bronchiectasis]. clinicaltrials.gov/ct2/show/NCT01677403 (first received 3 September 2012).

O’Donnell 1999 *(published data only)*


O’Donnell 2016 *(published data only)*


Orrioles 1999 *(published data only)*


Santiveri 1995 *(published data only)*


Serisier 2012 *(published data only)*


Shrewsbury 2004 *(published data only)*


Soyza 2015 *(published data only)*


Tabernero 2012 *(published data only)*


Terpstra 2016 *(published data only)*

Terpstra L, Altenburg J, Duijkers R, Boersma WG. Study design: effects of long term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis a double blind, randomized, placebo and TIS twice daily (open label) controlled trial.
Twiss 2008 [published data only]

Twiss 2009 [published data only]

Wilson 2011 [published data only]

Wong 2004 [published data only]

Chalmers 2015

Chalmers 2016

Chalmers JD 2012

Chang 2002

Chang 2003

Cystic Fibrosis Trust 2009

Donovan 2017

Dudley 2008

European Lung White Book 2013


Roberts 2010

Rubin 2008

Ryan 2011

Seitz 2010

Seitz 2012

Serisier 2013

Singleton 2000

Southern 2012

Welsh 2015

Weycker 2005

Wilson 2016

Wong 2012

Yang 2016

* Indicates the major publication for the study

---

**Oral versus inhaled antibiotics for bronchiectasis (Review)**

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### Characteristics of excluded studies [ordered by study ID]

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aksamit 2016</td>
<td>Wrong comparator. The trial compares inhaled ciprofloxacin to placebo</td>
</tr>
<tr>
<td>Alder 2011</td>
<td>Wrong comparator. The trial compares inhaled ciprofloxacin to placebo</td>
</tr>
<tr>
<td>Antoniu 2011</td>
<td>Wrong comparator. The trial compares inhaled gentamicin to placebo</td>
</tr>
<tr>
<td>Bilton 2006</td>
<td>Wrong intervention. The trial compares the addition of inhaled tobramycin to ciprofloxacin versus ciprofloxacin alone</td>
</tr>
<tr>
<td>Chalmers 2012</td>
<td>Not a randomised controlled trial. The study sought to investigate the impact of long- and short-term antibiotic treatment on inflammation</td>
</tr>
<tr>
<td>Fiel 2000</td>
<td>Wrong comparator. The trial compares inhaled tobramycin to placebo</td>
</tr>
<tr>
<td>Flume 2013</td>
<td>Wrong comparator. The trial compares inhaled aztreonam to placebo</td>
</tr>
<tr>
<td>Hampel 2011</td>
<td>Wrong comparator. The trial compares inhaled ciprofloxacin to placebo</td>
</tr>
<tr>
<td>Labiris 1999</td>
<td>Wrong comparator. The trial compared inhaled and nebulised gentamicin to intravenous gentamicin in a triple cross-over design</td>
</tr>
<tr>
<td>Ledson 2000</td>
<td>Letter to editor regarding “n of 1” trial of inhaled taurolidine versus placebo</td>
</tr>
<tr>
<td>Murray 2009</td>
<td>Wrong comparator. The trial compares inhaled gentamicin to placebo</td>
</tr>
<tr>
<td>NCT00749866 2008</td>
<td>Wrong comparator. The trial compares inhaled gentamicin to placebo</td>
</tr>
<tr>
<td>NCT01313624 2011</td>
<td>Wrong comparator. The trial compares inhaled aztreonam to placebo</td>
</tr>
<tr>
<td>NCT01677403 2012</td>
<td>Wrong comparator. The trial compares inhaled tobramycin to placebo</td>
</tr>
<tr>
<td>O’Donnell 1999</td>
<td>Wrong comparator. The trial compares inhaled tobramycin to placebo</td>
</tr>
<tr>
<td>O’Donnell 2016</td>
<td>Wrong comparator. The trial compares inhaled ciprofloxacin to placebo</td>
</tr>
<tr>
<td>Orriols 1999</td>
<td>Wrong comparator. The trial compares inhaled ceftazidime and tobramycin to usual care</td>
</tr>
<tr>
<td>Santiveri 1995</td>
<td>Wrong comparator. The trial compares addition of inhaled antibiotics to intravenous antibiotics versus intravenous antibiotics alone</td>
</tr>
<tr>
<td>Serisier 2012</td>
<td>Letter to editor regarding trial of inhaled gentamicin compares to placebo</td>
</tr>
<tr>
<td>Study</td>
<td>Intervention/Comparator</td>
</tr>
<tr>
<td>-------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>Shrewsbury 2004</td>
<td>Wrong intervention. The trial compares the addition of inhaled tobramycin to ciprofloxacin to ciprofloxacin alone</td>
</tr>
<tr>
<td>Soyza 2015</td>
<td>Wrong comparator. The trial compares inhaled ciprofloxacin to placebo</td>
</tr>
<tr>
<td>Taberneró 2012</td>
<td>Wrong comparator. The trial compares inhaled colistin to usual care</td>
</tr>
<tr>
<td>Terpstra 2016</td>
<td>Wrong comparator. The trial compares two different doses of inhaled tobramycin to placebo</td>
</tr>
<tr>
<td>Twiss 2008</td>
<td>Wrong comparator. The trial compares inhaled gentamicin to placebo</td>
</tr>
<tr>
<td>Twiss 2009</td>
<td>Wrong comparator. The trial compares inhaled gentamicin to placebo</td>
</tr>
<tr>
<td>Wilson 2011</td>
<td>Wrong comparator. The trial compares inhaled ciprofloxacin to placebo</td>
</tr>
<tr>
<td>Wong 2004</td>
<td>Wrong intervention and wrong comparator. Trial compares intravenous followed by oral antibiotics for an acute exacerbation of bronchiectasis, versus a full intravenous course of antibiotics</td>
</tr>
</tbody>
</table>
DATA AND ANALYSES

This review has no analyses.

CONTRIBUTIONS OF AUTHORS

PG and LF independently screened the search in consultation with SS, SJM and JDC. LF, SS and SJM completed the analyses and Results section. All review authors contributed to the Discussion, Conclusions and remaining sections of the review.

DECLARATIONS OF INTEREST

SS: is the lead applicant on a grant from Edge Hill University that provides support staff for a number of bronchiectasis reviews. She is also an editor with the Cochrane Airways Group.

LF: none known

SM: none known

RN: is Joint Co-ordinating Editor with the Cochrane Airways Group.

PCG: has received lecture fees from Novartis, Chiesi, Eurogenerics, Astra Zeneca and Boehringer and received travel accommodation from Chiesi and Novartis.

JDC: has received research funding from Astrazeneca and Pfizer, and has received lecture fees or served on advisory boards for Bayer, Griffols, Astrazeneca, Pfizer, Napp and Chiesi.

SOURCES OF SUPPORT

Internal sources
- Edge Hill University, UK.
Provided funding for a part-time review author (LF) to support a series of Cochrane Reviews on bronchiectasis.

External sources
- All authors, UK.
This review was completed, in part, through a grant of £5,000 from the Cochrane Review Support Programme.

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

As there are multiple manufacturers of both oral and inhaled antibiotics and many are off-patent, we did not conduct a search of manufacturers websites.